Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) and a pioneer in clinical genomic testing, today announced an enhancement to the Ambry CARE Program® (CARE), Ambry’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback